| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
SP001, an anti-CD40L antibody with potential across multiple immune-mediated diseases, advancing toward Phase 2 initiation in Immunoglobulin G4-related disease (IgG4-RD) |
| 12 Nov 2026 | 10-Q |
| 10 Nov 2026 |
Form 4: Rajavelu Esther, Director
Sold 40,851 shares ($42.5K) |
| 10 Nov 2026 |
Form 4: Ho William, Director
Granted 100,000 Stock Option (right to buy) |
| 10 Nov 2026 |
Form 3: Ho William, Director
No securities owned |
| 10 Nov 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 28 Oct 2026 | S-8 |
| 27 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 10 Sep 2026 | EFFECT |
| 28 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
On August 28, 2026, Spero Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an Open Market Sale Agreement℠ (the “Sale Agreement”) with Jefferies LLC, as agent (“Jefferies”), pursuant to which the Company may offer ... |
| 28 Aug 2026 | S-3 |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition
Entered an exclusive license agreement with Innovent Biologics for SP001, a Phase 2-ready, third-generation anti-CD40L antibody for immune-mediated diseases |
| 12 Aug 2026 | 10-Q |
| 06 Aug 2026 |
Form 4: Zack Debra, Chief Medical Officer
Received 162,311 shares as a grant or award · Granted 324,675 Stock option (right to buy) |
| 06 Aug 2026 |
Form 3: Zack Debra, Chief Medical Officer
No securities owned |
| 14 Jul 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more
On July 8, 2026, Spero Therapeutics, Inc. (the “Company”) entered into a license agreement (the “Innovent Agreement”) with Innovent Biologics (Suzhou) Co., Ltd. and Fortvita Biologics (USA), Inc. (collectively, “Innovent”), pursuant to w... |
| 25 Jun 2026 |
Form 4: Deshpande Milind, Director
Received 10,000 shares as a grant or award · Granted 20,000 Stock Option (right to buy) |
| 25 Jun 2026 |
Form 4: Tregoning Kathleen, Director
Received 10,000 shares as a grant or award · Granted 20,000 Stock Option (right to buy) |
| 25 Jun 2026 |
Form 4: Smith Cynthia, Director
Received 10,000 shares as a grant or award · Granted 20,000 Stock Option (right to buy) |
| 25 Jun 2026 |
Form 4: Vink Patrick V.j.j., Director
Received 10,000 shares as a grant or award · Granted 20,000 Stock Option (right to buy) |
Loading...